JP2015506352A5 - - Google Patents

Download PDF

Info

Publication number
JP2015506352A5
JP2015506352A5 JP2014549212A JP2014549212A JP2015506352A5 JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5 JP 2014549212 A JP2014549212 A JP 2014549212A JP 2014549212 A JP2014549212 A JP 2014549212A JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation according
treatment
antagonist
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014549212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506352A (ja
JP6224615B2 (ja
Filing date
Publication date
Priority claimed from US13/374,369 external-priority patent/US8946159B2/en
Application filed filed Critical
Publication of JP2015506352A publication Critical patent/JP2015506352A/ja
Publication of JP2015506352A5 publication Critical patent/JP2015506352A5/ja
Application granted granted Critical
Publication of JP6224615B2 publication Critical patent/JP6224615B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014549212A 2011-12-22 2012-12-18 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 Active JP6224615B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/374,369 US8946159B2 (en) 2011-12-22 2011-12-22 Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
US13/374,369 2011-12-22
PCT/US2012/070399 WO2013096335A1 (en) 2011-12-22 2012-12-18 Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment

Publications (3)

Publication Number Publication Date
JP2015506352A JP2015506352A (ja) 2015-03-02
JP2015506352A5 true JP2015506352A5 (enExample) 2016-05-19
JP6224615B2 JP6224615B2 (ja) 2017-11-01

Family

ID=48655153

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549212A Active JP6224615B2 (ja) 2011-12-22 2012-12-18 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与

Country Status (5)

Country Link
US (6) US8946159B2 (enExample)
EP (2) EP3777877B1 (enExample)
JP (1) JP6224615B2 (enExample)
CN (1) CN104159596B (enExample)
WO (1) WO2013096335A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
KR102102789B1 (ko) 2014-08-22 2020-04-24 내셔널 청쿵 유니버시티 디스인테그린 변이체 및 이의 약학적 용도
CA3092345A1 (en) * 2018-03-13 2019-09-19 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
EP4142707A4 (en) 2020-05-01 2024-09-18 The Regents of the University of California ALPHA-2-BETA-1 INTEGRIN INHIBITORS AND METHODS OF USE THEREOF
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734693A (en) 1992-03-17 1993-10-21 Board Of Regents, The University Of Texas System Neurotrophic peptides
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2044955A3 (en) * 1998-05-08 2009-04-29 The Regents of the University of California Methods for detecting and inhibiting angiogenesis
CA2400040A1 (en) * 2000-02-25 2001-08-30 Immunex Corporation Integrin antagonists
US20040121031A1 (en) 2002-12-09 2004-06-24 Muhammed Majeed Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin
US7101707B2 (en) 2002-12-23 2006-09-05 Cedars-Sinai Medical Center Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances
NZ549893A (en) 2004-03-24 2010-05-28 Facet Biotech Corp Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation
CN1933851B (zh) * 2004-03-24 2011-09-14 艾伯特生物治疗学公司 使用抗-α5β1抗体抑制癌细胞增殖
CA2611319A1 (en) * 2005-06-07 2006-12-14 William F. Degrado Inhibitors of the .alpha.2.beta.1/gpia-iia integrin
EP1984391A4 (en) 2006-01-19 2009-08-12 Eyegene Inc PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM
MX2008012225A (es) 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US20080267978A1 (en) 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
DK2268317T3 (da) 2008-03-14 2020-05-25 Visen Medical Inc Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
US20100105644A1 (en) 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
JP2012510466A (ja) 2008-12-01 2012-05-10 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤
WO2011146842A1 (en) 2010-05-20 2011-11-24 Temple University - Of The Commonwealth System Of Higher Education Process for synthesis of silane dipeptide analogs
US20110311335A1 (en) * 2010-06-21 2011-12-22 Douglas Wike Removable fastener
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
IL210587A0 (en) 2011-01-12 2011-03-31 Adel Jamil Hidmi Natural preparation for treatment of skin sores and lesions
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment

Similar Documents

Publication Publication Date Title
NZ706836A (en) Methods of treating cancer
JP2015506352A5 (enExample)
JP2014502638A5 (enExample)
JP2017505782A5 (enExample)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2015536964A5 (enExample)
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
JP2012255026A5 (enExample)
JP2010209081A5 (enExample)
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
JP2016533366A5 (enExample)
PL3791896T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
PH12016500164B1 (en) Therapeutically active compounds and their methods of use
JP2015500225A5 (enExample)
JP2016528162A5 (enExample)
JP2016520528A5 (enExample)
JP2017519027A5 (enExample)
MX2018012457A (es) Terapia combinatoria con inhibidores notch y cdk4/6.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
EP2682459A4 (en) ONCOLYTIC ADENOVIRES FOR A TEMPORARY THERAPY AND USE THEREOF
CL2013003230A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
JP2014523398A5 (enExample)